Adynxx, Inc announced that it has received $16 million in funding from TPG Biotech, Domain Associates, L.L.C., and another investor
January 08, 2017
Share
On January 9, 2017, Adynxx, Inc closed the transaction. The company announced that it has received $16,000,000 in its series B round of funding led by new investor, TPG Biotech. The transaction included participation from three investors including existing investor, Domain Associates, L.L.C. As a part of the transaction, Heath Lukatch of TPG Biotech has joined the company's board of directors.
Adynxx, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of a new class of therapeutics called transcription factor decoys and bringing to market disease-modifying products to address unmet needs in the treatment of pain and inflammation. The Company has leveraged its AYX platform of proprietary transcription factor decoys to identify and develop product candidates designed to modify the course of pain. Its product pipeline includes Brivoligide for postoperative pain and AYX2 for chronic pain. Brivoligide is a transcription factor decoy specifically designed to inhibit the function of transcription factor Early Growth Response 1 (EGR1), in the dorsal root ganglia (DRG), and spinal cord when administered at the time of surgery. Its second product candidate, AYX2, is a transcription factor decoy targeting the activity of specific members of the KLF family of transcription factors, including KLF6, KLF9 and KLF15.
ADYNXX, INC. 
